Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 15/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.43 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6542861 | 0.89 | KIT (0.49) | CHEK1KDRRETMAP3K20RIPK3 | |
| SCHEMBL6543102 | 0.84 | KDR (0.45) | KDRRETMAP3K20RIPK3WNT3A | |
| SCHEMBL446890 | 0.83 | KDR (0.63) | KDRRETMAP3K20RIPK3WNT3A | |
| SCHEMBL3106983 | 0.83 | KDR (0.46) | KDR | |
| SCHEMBL6543387 | 0.83 | CHEK1 (0.44) | CHEK1KDRRETMAP3K20RIPK3 | |
| SCHEMBL3119364 | 0.80 | KDR (0.45) | KDRRETMAP3K20RIPK3WNT3A | |
| SCHEMBL6542828 | 0.79 | KDR (0.49) | KDRRETMAP3K20RIPK3WNT3A | |
| SCHEMBL6543388 | 0.78 | KIT (0.48) | KDRRETMAP3K20RIPK3WNT3A | |
| SCHEMBL1490923 | 0.77 | KIT (0.51) | KDRRETMAP3K20RIPK3 | |
| SCHEMBL4588770 | 0.77 | KIT (0.61) | CHEK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254185-A1 | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254185-A1 | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 | FLT4, KDR, FLT1 | CHEK1 1533/4885KDR 2/4885RET 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.